Advert - Roche – Case AUTH/3639/4/22

For providing some, but not all, of the important information in relation to the administration of Polivy (polatuzumab vedotin), within a section of the promotional website that was intended to advise health professionals on the appropriate administration of the medicine and for not highlighting to the reader, on the dosing webpage, that additional important information in relation to dose modifications was within the safety webpage of the website, Roche was ruled in breach of the following clauses of the 2021 Code:

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1        - Failing to maintain high standards

Clause 6.1        - Providing misleading information